Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

Akçalı, Zafer; Çalıkuşu, Züleyha; Sakallı, Hakan; Ozyilkan, Ozgür

doi:10.1177/030089160809400406

Cited by 7 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median overall survival time was 13 months, and the median TTP and one-year survival rate was 6.2 months and 55.6%, respectively. These results are similar to those reported in Table 1 [9,11] . The main toxicity was myelosuppression.…”

Section: Gemcitabine and Dfdu Analysissupporting

confidence: 92%

“…Other eligibility criteria were as follows: age >18 years; acceptable hematologic parameters [white blood (cell) count (WBC) ≥3.5×10 9 /L, absolute neutrophil count (ANC) ≥1.5×10 9 /L, hemoglobin (HB) ≥10.0 g/L and platelets ≥100×10 9 /L]; and adequate hepatic and renal functions Patients were excluded for the following reasons: they were pregnant or lactating women; they had serious infection or organic disease; they had central nervous system (CNS) metastasis; they had other malignant tumors except for carcinoma of the cervix uteri in situ and basal cell carcinoma of the skin; or they had other symptoms that could influence the trial. The study was approved by the Ethics Committee of Zhejiang Cancer Hospital, and written informed consent was obtained from all patients.…”

Section: Patient Eligibility Criteriamentioning

confidence: 99%

“…While favorable response rates were observed, the dose schedule also resulted in increased rates of thrombocytopenia and neutropenia. Hematologic toxicity was less severe with a modified regimen employing a 3-week cycle with gemcitabine administration on d 1 and 8 [9][10][11][12][13] . In addition, both gemcitabine and cisplatin were given to patients with stage IIIB or IV NSCLC on the first day of every 2-week period [14] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

Fan

Lin

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

npg Aim: To investigate the pharmacodynamics and pharmacokinetics of gemcitabine (dFdC) administered on d 1 and 5 plus cisplatin administered on d 1 in chemonaive patients with stage IIIB or IV non-small cell lung cancer (NSCLC). Methods: In each combination cycle, gemcitabine was administered at a dose of 1250 mg/m 2 as a 30 min intravenous (iv) infusion on d 1 and 5 followed by cisplatin at a dose of 75 mg/m 2 as a 3 h iv infusion on d 1 every 3 weeks. There was an interval of 1 h between the two infusions. Clinical response and toxicity of the regimen were observed. Furthermore, the plasma concentrations of gemcitabine (dFdC) and its metabolite (dFdU) at different time points were detected during the first cycle of infusion. Pharmacokinetic software (PKS) was used to estimate the pharmacokinetic parameters of gemcitabine and its metabolite dFdU. Results: A total of 28 patients was enrolled in the study. The median age was 54 years (range 27-75 years), and most patients were in good clinical condition. Twenty-seven patients received two or more treatment cycles. The overall clinical response rate was 33.3%. The median overall survival time was 13 months. The estimated median time to tumor progression (TTP) was 6.2 months, and the 1-year survival rate was 55.6%. Toxicities were tolerated. The main toxicity was myelosuppression; 35.7% of patients had grade 3/4 hemato-logic toxicities and 28.6% had grade 3/4 non-hematologic toxicities, which were commonly gastrointestinal responses. The pharma-cokinetic parameters of dFdC and dFdU were not different between pre-and post-administration of gemcitabine on d 1 and 5. dFdU was minimal (0.729±0.637 μg/mL) before gemcitabine was infused on d 5, and gemcitabine was not present. Conclusion: The regimen is active and well tolerated in chemonaive patients with advanced NSCLC. After gemcitabine was administered on d 1 and 5, the pharmacokinetic parameters of dFdC and dFdU showed no difference from those before the infusion, and dFdU was minimal before gemcitabine was administered on d 5.

show abstract

Section: Gemcitabine and Dfdu Analysissupporting

confidence: 92%

Section: Patient Eligibility Criteriamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

Fan

Lin

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…Sixty-one patients received gemcitabine, given as two 1250-mg/m 2 doses on days 1 and 8 and, cisplatin, given as a 75-mg/m 2 dose on day 8 [ 13 ]. Twelve patients received vinorelbine given as two 25-mg/m 2 doses on day 1 and 8 and, cisplatin, given as a 75-mg/m 2 dose on day 1.…”

Section: Methodsmentioning

confidence: 99%

The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients

Çalıkuşu

Yıldırım

Akçalı

et al. 2009

J Exp Clin Cancer Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most widely used agents include Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel, and Iressa/Tarceva. By the administration of these chemo-agents, median survival of patients with advanced lung cancer have increased up to 12 months (10.9 months with Gemcitabine and Cisplatin [4], and 12.6 months with Pemetrexed and Cisplatin [5]). However, in far advanced lung cancer (stage IIIB or stage IV) the cure or complete remission of disease is hardly expected with chemotherapy only.…”

mentioning

confidence: 99%

The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients

Lee¹,

Park²,

Jung³

et al. 2015

ALC

View full text Add to dashboard Cite

Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have been tried in clinical practices, and oncothermia is supposed to be one of the promising candidates. From May 2008 to November 2013, 4 patients with far advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia in addition to conventional chemotherapy at Gangnam Severance Hospital and Bundang CHA Hospital. All these patients have survived for more than 2 years.

show abstract

Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8

Cited by 7 publications

References 25 publications

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients

The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients

Contact Info

Product

Resources

About